The Life Science business of Merck KGaA, Darmstadt, Germany Acquires HUB Organoids Holding B.V., Expands Next-Gen Biology Portfolio

Featured Story

The Life Science business of Merck KGaA, Darmstadt, Germany Acquires HUB Organoids Holding B.V., Expands Next-Gen Biology Portfolio

Reinforces company’s commitment to differentiated solutions that enable faster and more effective drug development HUB’s organoid offering complements company’s cell...

Read More

More from HUB

HUB Organoids Launches IntegriGut Screen: A Breakthrough Service Offering for Inflammatory Bowel Disease (IBD) Drug Discovery and Development

HUB Organoids Launches IntegriGut Screen: A Breakthrough Service Offering for Inflammatory Bowel Disease (IBD) Drug Discovery and Development

Utrecht, Netherlands – 25th Jan 2024 – HUB Organoids (HUB), a global leader and sole proprietor of patient-derived organoid technology...

HUB Organoids Announces New Corporate Strategy and Completes Transition from Foundation to Private Company

HUB Organoids Announces New Corporate Strategy and Completes Transition from Foundation to Private Company

[Utrecht, July 18 2023] — HUB Organoids (HUB), the global leader in the field of patient-derived organoids, is excited to...

FDA Modernization Act 2.0: We welcome the dawn of an organoid era

FDA Modernization Act 2.0: We welcome the dawn of an organoid era

X

Have any questions?

contact us